Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLIN-B-ALL consolidation study in intermediate-risk pediatric and adolescent B-cell ALL
jRCT2031230581Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Event-free survival. Started Feb 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2031230581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230581.